2-hydroxy-3-[(5-oxo-1,3-diphenylpyrazol-4-ylidene)methyl]pyrido[1,2-a]pyrimidin-4-one
C24H16N4O3 — CID 137224590
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-hydroxy-3-[(5-oxo-1,3-diphenylpyrazol-4-ylidene)methyl]pyrido[1,2-a]pyrimidin-4-one
2-hydroxy-3-[(5-oxo-1,3-diphenylpyrazol-4-ylidene)methyl]pyrido[1,2-a]pyrimidin-4-one (PubChem CID 137224590) has the molecular formula C24H16N4O3 and a molecular weight of 408.42 g/mol. Its IUPAC name is 2-hydroxy-3-[(5-oxo-1,3-diphenylpyrazol-4-ylidene)methyl]pyrido[1,2-a]pyrimidin-4-one.
Molecular Properties
| Compound Name | 2-hydroxy-3-[(5-oxo-1,3-diphenylpyrazol-4-ylidene)methyl]pyrido[1,2-a]pyrimidin-4-one |
|---|---|
| PubChem CID | 137224590 |
| Molecular Formula | C24H16N4O3 |
| Molecular Weight | 408.42 g/mol |
| Exact Mass | 408.12 |
| IUPAC Name | 2-hydroxy-3-[(5-oxo-1,3-diphenylpyrazol-4-ylidene)methyl]pyrido[1,2-a]pyrimidin-4-one |
| SMILES | O=C1C(=Cc2c(O)nc3ccccn3c2=O)C(c2ccccc2)=NN1c1ccccc1 |
| InChI | InChI=1S/C24H16N4O3/c29-22-19(23(30)27-14-8-7-13-20(27)25-22)15-18-21(16-9-3-1-4-10-16)26-28(24(18)31)17-11-5-2-6-12-17/h1-15,29H |
| InChIKey | XCAJAIFWCSQMAM-UHFFFAOYSA-N |
| XLogP | 3.23 |
| TPSA | 87.27 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 408.42 |
| LogP ≤ 5 | 3.23 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'ene_five_het_A(201)', 'substructure': 'N/A'}, {'alert_name': 'Michael_acceptor_1', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 137224590 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.